No annual revenue total was found in Telomir Pharmaceuticals, Inc.'s SEC filings.
Telomir Pharmaceuticals, Inc. (TELO) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income (TTM)
$-5.88M
+63.5% vs year-ago TTM
Operating cash flow (TTM)
$-4.91M
-55.1% vs year-ago TTM
Free cash flow
—
EPS (TTM)
$-0.15
+72.8% vs year-ago TTM
Dividend per share
None
Shares outstanding
34.38M
+15.5% vs prior year
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- TELO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- FL
- Headquarters
- Miami, FL
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1971532
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
|---|---|---|---|
| Net income | -$10.4M | -$16.5M | -$13.1M |
| Diluted EPS | -$0.33 | -$0.56 | $0.48 |
| Operating cash flow | -$3.7M | -$5.1M | -$3.9M |
| Total assets | $7.3M | $1.3M | $4.8M |
| Total liabilities | $1.4M | $680,968 | $1.3M |
| Stockholders' equity | $5.9M | $643,037 | $3.4M |
| Cash and investments | $7.3M | $1.3M | $1,231 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Oct 6, 2026 | Oct 5, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 17, 2026 | Sep 17, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Sep 16, 2026 | Sep 11, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 14, 2026 | Sep 14, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Aug 10, 2026 | Aug 10, 2026 |
All 147 Telomir Pharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.